193 related articles for article (PubMed ID: 27764122)
1. Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
Pochechueva T; Chinarev A; Schoetzau A; Fedier A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V
PLoS One; 2016; 11(10):e0164230. PubMed ID: 27764122
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients.
Pochechueva T; Alam S; Schötzau A; Chinarev A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V
J Ovarian Res; 2017 Feb; 10(1):8. PubMed ID: 28187738
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
[No Abstract] [Full Text] [Related]
4. Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array.
Jacob F; Goldstein DR; Bovin NV; Pochechueva T; Spengler M; Caduff R; Fink D; Vuskovic MI; Huflejt ME; Heinzelmann-Schwarz V
Int J Cancer; 2012 Jan; 130(1):138-46. PubMed ID: 21351089
[TBL] [Abstract][Full Text] [Related]
5. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels.
Coticchia CM; Curatolo AS; Zurakowski D; Yang J; Daniels KE; Matulonis UA; Moses MA
Gynecol Oncol; 2011 Nov; 123(2):295-300. PubMed ID: 21889192
[TBL] [Abstract][Full Text] [Related]
6. Glycomics analysis of serum: a potential new biomarker for ovarian cancer?
Leiserowitz GS; Lebrilla C; Miyamoto S; An HJ; Duong H; Kirmiz C; Li B; Liu H; Lam KS
Int J Gynecol Cancer; 2008; 18(3):470-5. PubMed ID: 17655680
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
[TBL] [Abstract][Full Text] [Related]
8. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
10. Comparison of printed glycan array, suspension array and ELISA in the detection of human anti-glycan antibodies.
Pochechueva T; Jacob F; Goldstein DR; Huflejt ME; Chinarev A; Caduff R; Fink D; Hacker N; Bovin NV; Heinzelmann-Schwarz V
Glycoconj J; 2011 Dec; 28(8-9):507-17. PubMed ID: 21948103
[TBL] [Abstract][Full Text] [Related]
11. Single and combined use of red cell distribution width, mean platelet volume, and cancer antigen 125 for differential diagnosis of ovarian cancer and benign ovarian tumors.
Qin YY; Wu YY; Xian XY; Qin JQ; Lai ZF; Liao L; Lin FQ
J Ovarian Res; 2018 Jan; 11(1):10. PubMed ID: 29357908
[TBL] [Abstract][Full Text] [Related]
12. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
13. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay.
Horala A; Swiatly A; Matysiak J; Banach P; Nowak-Markwitz E; Kokot ZJ
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075407
[TBL] [Abstract][Full Text] [Related]
15. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
16. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?
Azzam AZ; Hashad DI; Kamel NA
Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457
[TBL] [Abstract][Full Text] [Related]
18. Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma.
Mikami M; Tanabe K; Matsuo K; Miyazaki Y; Miyazawa M; Hayashi M; Asai S; Ikeda M; Shida M; Hirasawa T; Kojima N; Sho R; Iijima S
Gynecol Oncol; 2015 Dec; 139(3):520-8. PubMed ID: 26477941
[TBL] [Abstract][Full Text] [Related]
19. Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
Shah JS; Gard GB; Yang J; Maidens J; Valmadre S; Soon PS; Marsh DJ
Gynecol Oncol; 2018 Jan; 148(1):181-188. PubMed ID: 29132874
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Buas MF; Gu H; Djukovic D; Zhu J; Drescher CW; Urban N; Raftery D; Li CI
Gynecol Oncol; 2016 Jan; 140(1):138-44. PubMed ID: 26521694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]